

# Simone Lista

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/863454/simone-lista-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138  
papers

4,987  
citations

36  
h-index

67  
g-index

153  
ext. papers

6,562  
ext. citations

5  
avg, IF

5.58  
L-index

#	Paper	IF	Citations
138	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 292-323	1.2	832
137	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 639-652	15	257
136	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 45-58 <sup>1.2</sup>	1.2	163
135	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 549-60	1.2	159
134	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , <b>2018</b> , 19, 244-328	3.8	148
133	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 465-476	1.2	127
132	Cognitive and neuroimaging features and brain amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 335-346	24.1	113
131	Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. <i>Medical Clinics of North America</i> , <b>2013</b> , 97, 399-424	7	108
130	The B-secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , <b>2021</b> , 89, 745-756	7.9	107
129	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. <i>Alzheimer's and Dementia</i> , <b>2012</b> , 8, 312-36	1.2	92
128	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. <i>Progress in Neurobiology</i> , <b>2013</b> , 101-102, 1-17	10.9	88
127	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1306-15	1.2	87
126	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 456	8.4	87
125	Plasma amyloid A $\beta$ 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 764-775	1.2	86
124	A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. <i>Climacteric</i> , <b>2017</b> , 20, 107-118	3.1	84
123	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 64, S47-S105	4.3	84
122	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , <b>2014</b> , 88, 426-49	6	84

121	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1041-9	1.2	78
120	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A $\beta$ total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 492-501	1.2	71
119	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 59-71	1.2	70
118	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , <b>2018</b> , 83, 447-455	7.9	62
117	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 47, 291-317	7.3	61
116	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , <b>2018</b> , 130, 331-365	10.2	60
115	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 83-105	4.3	53
114	Exercise benefits on Alzheimer's disease: State-of-the-science. <i>Ageing Research Reviews</i> , <b>2020</b> , 62, 101108	10.8	53
113	CSF A $\beta$ 42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 381-92	1.2	53
112	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 11706	4.9	53
111	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , <b>2017</b> , 14, 285-299	4.2	49
110	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 454-467	1.2	49
109	Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 1231-5	5.6	49
108	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 68, 1-24	4.3	48
107	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. <i>Brain</i> , <b>2019</b> , 142, 2096-2112	11.2	47
106	Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2017</b> , 17, 47-57	4.3	44
105	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1204-1215	1.2	40
104	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , <b>2017</b> , 108, 355-360	4.4	38

103	Biological and methodical challenges of blood-based proteomics in the field of neurological research. <i>Progress in Neurobiology</i> , <b>2013</b> , 101-102, 18-34	10.9	38
102	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 993-1003	1.2	35
101	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2016</b> , 3, 27-34	5.2	35
100	Paths to Alzheimer's disease prevention: From modifiable risk factors to biomarker enrichment strategies. <i>Journal of Nutrition, Health and Aging</i> , <b>2015</b> , 19, 154-63	5.2	34
99	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. <i>Annals of Nuclear Medicine</i> , <b>2018</b> , 32, 75-86	2.5	33
98	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 940-950	1.2	31
97	Imaging epigenetics in Alzheimer's disease. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 6393-415	3.3	31
96	Association of cerebrospinal fluid $\beta$ -synuclein with total and phospho-tau protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1623-1631	1.2	30
95	Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1303, 49-67	1.4	29
94	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , <b>2018</b> , 50, 31-51	8.9	29
93	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <i>Journal of Neurology</i> , <b>2014</b> , 261, 1234-43	5.5	29
92	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 48 Suppl 1, S171-91	4.3	29
91	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 59, 1327-1334	4.3	28
90	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 69, 615-629	4.3	28
89	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 585432	5.1	28
88	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , <b>2019</b> , 181, 101662	10.9	26
87	Optimization protocol for amyloid- $\beta$ peptides detection in human cerebrospinal fluid using SELDI TOF MS. <i>Proteomics - Clinical Applications</i> , <b>2010</b> , 4, 352-7	3.1	26
86	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. <i>Trends in Neurosciences</i> , <b>2017</b> , 40, 469-480	13.3	25

85	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e1631-e1638	4.6	25
84	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. <i>Journal of Nutrition, Health and Aging</i> , <b>2013</b> , 17, 54-63	5.2	24
83	Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. <i>Learning and Memory</i> , <b>2010</b> , 17, 236-40	2.8	24
82	Disrupted white matter structural networks in healthy older adult APOE ε carriers - An international multicenter DTI study. <i>Neuroscience</i> , <b>2017</b> , 357, 119-133	3.9	23
81	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , <b>2019</b> , 83, 42-53	5.6	23
80	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 310	5.6	23
79	Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1750, 31-66	1.4	23
78	The phenotypical core of Alzheimer's disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 786-95	1.2	21
77	Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 877-86	4.3	21
76	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , <b>2019</b> , 16, 593-600	4.2	20
75	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 48, 793-804	4.3	20
74	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2015</b> , 265, 5-18	5.1	19
73	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2015</b> , 265, 19-30	5.1	19
72	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 421-441	3.8	19
71	Biomarker-guided classification scheme of neurodegenerative diseases. <i>Journal of Sport and Health Science</i> , <b>2016</b> , 5, 383-387	8.2	19
70	Coronavirus Lockdown: Forced Inactivity for the Oldest Old?. <i>Journal of the American Medical Association</i> , <b>2020</b> , 21, 988-989	5.9	18
69	Dementia: The rising global tide of cognitive impairment. <i>Nature Reviews Neurology</i> , <b>2016</b> , 12, 131-2	15	18
68	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 67	5.3	18

67	Successful aging: insights from proteome analyses of healthy centenarians. <i>Aging</i> , <b>2020</b> , 12, 3502-3515	5.6	18
66	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 642	4.1	18
65	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , <b>2021</b> , 69, 101346	12	17
64	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- $\beta$ Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , <b>2019</b> , 290, 167-176	20.5	15
63	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , <b>2020</b> , 57, 4667-4691	6.2	14
62	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease?. <i>Dialogues in Clinical Neuroscience</i> , <b>2019</b> , 21, 177-191	5.7	13
61	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. <i>Neurobiology of Aging</i> , <b>2017</b> , 57, 143-152	5.6	13
60	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , <b>2020</b> , 94, e30-e41	6.5	13
59	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , <b>2016</b> , 108, 128-35	5.5	12
58	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , <b>2020</b> , 90, 43-59	5.6	12
57	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , <b>2021</b> , 185, 108081	5.5	12
56	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1126-1136	1.2	12
55	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1598, 101-115	1.4	11
54	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2020</b> , 93, 98-108	5.6	10
53	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , <b>2017</b> , 19, 154-160	4.6	10
52	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1750, 139-155	1.4	10
51	Brain A $\beta$ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1274-1285	1.2	9
50	Blood-based diagnostics of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , <b>2019</b> , 19, 613-628	3.8	8

49	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 129	9	8
48	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 147	9	8
47	Physical Exercise and Alzheimer's Disease: Effects on Pathophysiological Molecular Pathways of the Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	8
46	The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 57	9	7
45	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , <b>2016</b> , 249, 84-90	2.9	7
44	Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. <i>PLoS ONE</i> , <b>2018</b> , 13, e0190212	3.7	6
43	MiRNA-15b and miRNA-125b are associated with regional AβPET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 78	8.6	6
42	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 553-562	6	5
41	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	5
40	Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. <i>Ageing Research Reviews</i> , <b>2021</b> , 72, 101479	12	5
39	Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , <b>2013</b> , 5, 11	9	4
38	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 151-161	4.3	4
37	Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , <b>2020</b> , 96, 22-32	5.6	4
36	Plasma β-secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 629-640	1.2	4
35	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , <b>2020</b> , 88, 83-90	5.6	3
34	β-secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 130	9	2
33	Commentary: Development of the Blood-Based Alzheimer's Disease Liquid Biopsy. <i>Journal of prevention of Alzheimer's disease, The</i> , <b>2019</b> , 6, 182-184	3.8	1
32	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA <b>2014</b> , 10, P541-P542		1

31	[P2879]: ACCURACY OF MRI CLASSIFICATION ALGORITHMS IN A TERTIARY MEMORY CENTER CLINICAL ROUTINE COHORT <b>2017</b> , 13, P772-P774		1
30	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 577-583	4.3	1
29	Potential therapeutical effects of topical halofuginone hydrobromide in keloid management. <i>Medical Hypotheses</i> , <b>2007</b> , 69, 707	3.8	1
28	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 748198	5.3	1
27	Aptamer prediction of brain amyloid- $\beta$ status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0243902	3.7	1
26	P3-218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: A $\beta$ -42, TOTAL-TAU, PHOSPHORYLATED-TAU, NFL, NEUROGRANIN, AND YKL-40 <b>2018</b> , 14, P1154-P1155		1
25	P1-431: APOE-DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS <b>2018</b> , 14, P474-P474		1
24	Association of plasma A $\beta$ 0/A $\beta$ 2 ratio and brain A $\beta$ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2021</b> , 107, 57-69	5.6	1
23	Defining and assessing intrinsic capacity in older people: a systematic review and a proposed scoring system.. <i>Ageing Research Reviews</i> , <b>2022</b> , 101640	12	1
22	Exercise and the hallmarks of peripheral arterial disease.. <i>Atherosclerosis</i> , <b>2022</b> , 350, 41-50	3.1	0
21	Association of plasma YKL-40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e041753	1.2	
20	Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e041792	1.2	
19	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045832	1.2	
18	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e046014	1.2	
17	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e046105	1.2	
16	Schizophrenia: Blood-Serum-Plasma Metabolomics. <i>Advances in Biological Psychiatry</i> , <b>2014</b> , 27-27		
15	IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA <b>2014</b> , 10, P37-P37		
14	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. <i>Medical Hypotheses</i> , <b>2008</b> , 71, 162	3.8	



- 13 Analysis of mitochondrial DNA by PCR/DHPLC as a diagnostic tool to differentiate schistosomes species and strains. *Medical Hypotheses*, **2007**, 68, 707-8 3.8
- 12 Demineralized bone matrix enriched with human recombinant interleukin-11: a novel therapeutic option in treatment of delayed unions and nonunions?. *Medical Hypotheses*, **2007**, 69, 954 3.8
- 11 An expanded microarray platform for diagnosis of nonbacterial sepsis: potential usefulness for immunosuppressed patients. *Medical Hypotheses*, **2006**, 67, 1001 3.8
- 10 P4-072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL **2018**, 14, P1461-P1462
- 9 P2-237: ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS **2018**, 14, P762-P762
- 8 O4-07-04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN **2018**, 14, P1419-P1420
- 7 O3-09-02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOID-PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS **2018**, 14, P1036-P1037
- 6 P4-186: INNOVATIVE BIOMARKER-GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA **2018**, 14, P1510-P1511
- 5 P2-397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN **2018**, 14, P855-P856
- 4 P2-246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKL-40 CONCENTRATIONS IN AMYLOID-PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS **2018**, 14, P767-P768
- 3 P2-249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS **2018**, 14, P768-P769
- 2 O3-12-04: THE NEURONAL COMPENSATION MODEL OF THE PRECLINICAL STAGE OF ALZHEIMER'S DISEASE: RESULTS FROM THE INSIGHT-PRE AD STUDY **2018**, 14, P1051-P1053
- 1 P2-355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS **2018**, 14, P824-P825